MaltSci 麦伴科研

Appearance

Popular Reports / Immunology

This report is written by MaltSci based on the latest literature and research findings

What are the mechanisms of allergic reactions? ​

Abstract ​

Allergic reactions represent a significant public health concern, affecting around 40% of the global population. These reactions arise from inappropriate immune responses to harmless environmental antigens, known as allergens, leading to various clinical manifestations such as allergic rhinitis, asthma, food allergies, and anaphylaxis. The underlying mechanisms of allergic reactions are complex, involving interactions between immune cells, mediators, and environmental factors. This review synthesizes current knowledge regarding the immunological mechanisms of allergic reactions, emphasizing the roles of immunoglobulin E (IgE), mast cells, and cytokines, as well as genetic predispositions and environmental triggers that contribute to allergy development. Upon exposure to allergens, IgE binds to high-affinity receptors on mast cells and basophils, leading to their activation and degranulation, which releases pro-inflammatory mediators like histamine and cytokines. This immediate response is often followed by a late-phase reaction characterized by eosinophilic infiltration and chronic inflammation, driven by Th2 cells. The review also addresses genetic factors influencing allergies, including genetic predisposition and epigenetic modifications that can alter immune responses. Environmental triggers such as common allergens and the impact of urbanization and lifestyle changes on allergy prevalence are discussed. Finally, current and emerging treatment options, including pharmacological approaches and immunotherapy, are reviewed, highlighting future directions for allergy management. Understanding these mechanisms is essential for developing effective treatments and preventive strategies to manage allergic diseases.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Mechanisms of Allergic Reactions
    • 2.1 Role of Immunoglobulin E (IgE)
    • 2.2 Activation of Mast Cells and Basophils
    • 2.3 Cytokine Production and Immune Response
  • 3 Genetic Factors Influencing Allergies
    • 3.1 Genetic Predisposition
    • 3.2 Role of Epigenetics
  • 4 Environmental Triggers of Allergic Reactions
    • 4.1 Common Allergens
    • 4.2 Impact of Urbanization and Lifestyle Changes
  • 5 Current and Emerging Treatments
    • 5.1 Pharmacological Approaches
    • 5.2 Immunotherapy
    • 5.3 Future Directions in Allergy Management
  • 6 Summary

1 Introduction ​

Allergic reactions are increasingly recognized as a significant public health concern, affecting approximately 40% of the global population. These reactions arise from an inappropriate immune response to typically harmless environmental antigens, known as allergens, which can lead to a variety of clinical manifestations, including allergic rhinitis, asthma, food allergies, and anaphylaxis. The mechanisms underlying these reactions are complex and involve intricate interactions between various immune cells, mediators, and environmental factors. Understanding these mechanisms is essential for developing effective treatments and preventive strategies to manage allergic diseases, which have seen a dramatic rise in prevalence over recent decades, particularly in developed countries [1][2].

The significance of elucidating the mechanisms of allergic reactions cannot be overstated. Allergies not only contribute to individual morbidity but also impose substantial healthcare costs and societal burdens. As the incidence of allergic diseases continues to rise, particularly among children and young adults, there is an urgent need to identify the biological pathways that govern these responses [3][4]. This review aims to synthesize current knowledge regarding the immunological mechanisms of allergic reactions, focusing on the role of immunoglobulin E (IgE), mast cells, and cytokines, while also addressing genetic predispositions and environmental triggers that contribute to allergy development [5][6].

Recent advancements in immunology have highlighted the pivotal role of IgE in mediating immediate hypersensitivity reactions. Upon exposure to an allergen, IgE binds to high-affinity receptors on mast cells and basophils, leading to the release of various pro-inflammatory mediators, such as histamine and cytokines [1][7]. This immediate response is often followed by a late-phase reaction characterized by eosinophilic infiltration and chronic inflammation, primarily driven by T helper type 2 (Th2) cells that secrete cytokines like IL-4, IL-5, and IL-13 [5][6]. The dysregulation of these immune pathways not only perpetuates allergic inflammation but also complicates treatment approaches, necessitating a deeper understanding of the underlying mechanisms [2][8].

The review is organized as follows: First, we will explore the mechanisms of allergic reactions, focusing on the roles of IgE, mast cell activation, and cytokine production. Next, we will examine genetic factors influencing allergies, including genetic predisposition and epigenetic modifications that can alter immune responses. Following this, we will discuss environmental triggers, such as common allergens and the impact of urbanization and lifestyle changes on allergy prevalence. Finally, we will review current and emerging treatment options, including pharmacological approaches and immunotherapy, and highlight future directions for allergy management. By synthesizing these elements, this review aims to provide a comprehensive overview of the current understanding of allergic reactions and their implications for clinical practice and public health [2][5][6].

In conclusion, the interplay of genetic, immunological, and environmental factors in allergic diseases underscores the complexity of these conditions. A better understanding of the mechanisms involved will not only enhance our ability to diagnose and treat allergies but also inform public health strategies aimed at mitigating their impact. This review seeks to illuminate these critical aspects of allergic reactions, paving the way for improved management and prevention strategies in the face of a growing allergy epidemic.

2 Mechanisms of Allergic Reactions ​

2.1 Role of Immunoglobulin E (IgE) ​

Immunoglobulin E (IgE) plays a pivotal role in the mechanisms underlying allergic reactions, particularly through its interactions with specific receptors on effector cells such as mast cells and basophils. Upon exposure to allergens, IgE mediates immediate hypersensitivity responses, leading to the release of inflammatory mediators and the subsequent clinical manifestations of allergic diseases.

The primary mechanism begins with the binding of allergens to IgE antibodies that are already bound to high-affinity IgE receptors (FcεRI) on mast cells and basophils. This cross-linking of IgE by multivalent allergens triggers a cascade of intracellular signaling events that result in the activation and degranulation of these effector cells. The degranulation process releases various pro-inflammatory mediators, including histamine, leukotrienes, and cytokines, which contribute to the symptoms of allergic reactions such as itching, swelling, and bronchoconstriction [9][10][11].

In addition to FcεRI, IgE also interacts with low-affinity IgE receptors (CD23). This interaction plays a regulatory role in IgE-mediated immune responses, including the modulation of IgE synthesis and the presentation of allergen-IgE complexes to T cells. CD23 can influence the growth and differentiation of B and T cells, thereby enhancing the overall immune response to allergens [12][13].

Furthermore, the production of IgE is tightly regulated by various cytokines, particularly interleukin-4 (IL-4) and interleukin-13 (IL-13), which are produced by T helper type 2 (Th2) cells, mast cells, and basophils. These cytokines promote the differentiation of B cells into IgE-secreting plasma cells, facilitating the generation of allergen-specific IgE [14][15]. The presence of IgE is a hallmark of allergic diseases, including allergic rhinitis, asthma, and atopic dermatitis [5][16].

Recent advancements in the understanding of IgE biology have led to the development of therapeutic strategies aimed at modulating IgE function. Anti-IgE therapies, such as omalizumab, target free IgE in circulation to prevent its binding to FcεRI, thereby reducing allergic responses. Additionally, newer classes of "disruptive" IgE inhibitors are being developed to actively dismantle preformed IgE-receptor complexes, potentially offering rapid desensitization of allergic effector cells [10][16].

In summary, the mechanisms of allergic reactions primarily involve the critical role of IgE in mediating immediate hypersensitivity responses through its interaction with high- and low-affinity receptors on mast cells and basophils. The intricate regulation of IgE production and function is central to the pathogenesis of allergic diseases, and ongoing research continues to explore innovative therapeutic approaches to mitigate these responses.

2.2 Activation of Mast Cells and Basophils ​

Allergic reactions are complex processes primarily involving the activation of mast cells and basophils, which are crucial effector cells in the immune system. The activation of these cells is primarily mediated through immunoglobulin E (IgE) and its interaction with high-affinity IgE receptors (FcεRI) present on the surface of mast cells and basophils. Upon exposure to an allergen, the allergen binds to IgE that is already attached to these receptors, leading to cross-linking and subsequent cellular activation.

The activation of mast cells and basophils triggers the release of various preformed and newly synthesized mediators, including histamine, leukotrienes, and cytokines, which are responsible for the symptoms associated with allergic reactions such as asthma, allergic rhinitis, and anaphylaxis. Mast cells are particularly noted for their role in the "early phase" of allergic reactions, characterized by rapid mediator release, while the "late phase" involves the infiltration of inflammatory cells, including eosinophils, into the affected tissues [17].

The signaling pathways activated during mast cell and basophil activation are influenced by several factors. For mast cells, the stem cell factor (SCF) plays a pivotal role in their development and activation via its receptor, KIT. The interaction between SCF and KIT has been shown to cross-talk with FcεRI signaling pathways, which is crucial for the mast cell's response to allergens [18]. Moreover, mast cells and basophils exhibit unique adhesion and migration responses that facilitate their selective recruitment to tissues during allergic inflammation. These responses are modulated by specific stimuli and the expression levels of cell surface molecules involved in adhesion [19].

Basophils, although historically considered less significant than mast cells in acute allergic reactions, have been shown to play an important role in rapid allergic responses. Recent studies suggest that basophils migrate quickly upon allergen exposure and may contribute significantly to the clinical symptoms of anaphylaxis. Their trafficking during allergic reactions can be either pathogenic or protective, highlighting their complex role in allergic diseases [20].

Furthermore, the pharmacological modulation of mediator release from mast cells and basophils is an area of ongoing research. Various pharmacological agents can inhibit mediator release, providing potential therapeutic avenues for managing allergic reactions [21]. Understanding the precise mechanisms of mast cell and basophil activation, as well as their unique roles in allergic responses, is critical for developing effective treatments for allergic diseases.

2.3 Cytokine Production and Immune Response ​

Allergic reactions are complex immunological responses that involve both innate and adaptive immunity. The mechanisms underlying these reactions can be categorized into sensitization and elicitation phases, with cytokines playing a crucial role throughout the process.

The initial phase of an allergic reaction begins with sensitization, where an individual is exposed to an allergen. This exposure leads to the production of immunoglobulin E (IgE) antibodies by B cells, a process that is predominantly driven by T helper type 2 (TH2) cells. These TH2 cells secrete specific cytokines such as interleukin (IL)-4, IL-5, and IL-13, which facilitate IgE synthesis and promote the differentiation and survival of eosinophils. Notably, these cytokines are produced in significant amounts during allergic responses but do not induce interferon-gamma, which is characteristic of other immune responses (Leung 1998; Leung 1997).

Upon subsequent exposure to the same allergen, the allergen binds to IgE antibodies that are already bound to high-affinity IgE receptors on mast cells and basophils. This cross-linking triggers the degranulation of these cells, resulting in the rapid release of various mediators, including histamines, leukotrienes, and prostaglandins. These mediators are responsible for the immediate symptoms of allergic reactions, such as anaphylaxis, urticaria, and allergic asthma (Averbeck et al. 2007).

Following the immediate response, a late-phase reaction occurs, characterized by the infiltration of eosinophils and T lymphocytes. The late-phase response is predominantly mediated by eosinophils, which are attracted to the site of allergen exposure by chemokines and cytokines released during the initial response. The continued presence of TH2 cytokines contributes to this eosinophilic infiltration, exacerbating the inflammatory response and leading to chronic symptoms if the immune activation is not adequately controlled (Leung 1998; Leung 1997).

Cytokines not only facilitate the activation and recruitment of immune cells but also play a role in regulating the expression of adhesion molecules that mediate the interaction between leukocytes and endothelial cells. This regulation is essential for the migration of immune cells to sites of inflammation (Bittleman and Casale 1994).

Moreover, the dysregulation of cytokine production and signaling pathways can lead to the persistence of allergic inflammation. Therapeutic strategies targeting specific cytokines and their signaling pathways are being developed to manage allergic diseases effectively. These approaches include the use of biologics that specifically inhibit cytokine activity, thereby reducing the overall inflammatory response and improving patient outcomes (Lawrence et al. 2018).

In summary, the mechanisms of allergic reactions are multifaceted, involving the intricate interplay of various immune cells and cytokines. The activation of TH2 cells and the subsequent production of cytokines are pivotal in both the sensitization and elicitation phases of allergic responses, ultimately contributing to the characteristic symptoms of allergic diseases. Understanding these mechanisms is crucial for developing targeted therapies aimed at alleviating the burden of allergic conditions.

3 Genetic Factors Influencing Allergies ​

3.1 Genetic Predisposition ​

Allergic reactions, particularly type I hypersensitivity, are characterized by a misdirected immune overreaction to harmless environmental and dietary antigens known as allergens. The underlying mechanisms of these reactions are complex and involve both genetic and environmental factors.

Genetic predisposition plays a significant role in the development of allergic diseases, often referred to as atopy. This predisposition can manifest in various forms, including allergic rhinitis, allergic conjunctivitis, atopic dermatitis, allergic asthma, and even anaphylaxis [1]. The impact of genetic factors on the pathogenesis of allergies and asthma has been the focus of intense research. Although numerous genes have been implicated in contributing to allergic inflammation, understanding the functional mechanisms linking genetic variations to the dysregulation of gene expression remains challenging due to the high frequency of natural genetic variation [22].

Moreover, recent studies emphasize the interplay between genetic factors and environmental influences, which adds complexity to the determination of allergic phenotypes. The environment can significantly modify the expression of genetic predispositions, leading to variations in clinical symptoms [23]. For instance, epigenetic mechanisms, including DNA methylation and histone modifications, can alter gene expression and immune responses, further complicating the genetic landscape of allergies [24].

Genome-wide association studies (GWAS) have identified numerous susceptibility loci associated with allergic diseases. These loci include genes involved in epithelial barrier functions, innate and adaptive immunity, and signaling pathways related to interleukin-1 and vitamin D, which are crucial in the pathogenesis of allergies [25][26]. Notably, regions such as IL1RL1, HLA, IL13, and C11orf30 have been found to overlap among different allergic conditions, indicating a shared genetic background [25].

Furthermore, prenatal and postnatal environmental exposures, including dietary components and microbial interactions, have been shown to influence the development of the immune system and its response to allergens [27]. These interactions may lead to epigenetic modifications that predispose individuals to allergic diseases later in life [27].

In summary, the mechanisms of allergic reactions are intricately linked to genetic predisposition and environmental factors. The interaction between these elements contributes to the pathophysiology of allergic diseases, emphasizing the need for an integrated approach to understand and manage these conditions effectively.

3.2 Role of Epigenetics ​

Allergic reactions, particularly type I hypersensitivity reactions, are characterized by a misdirected immune response to typically harmless environmental and dietary antigens known as allergens. The underlying mechanisms of these allergic reactions involve a complex interplay of genetic, immunologic, and environmental factors. Genetic predisposition, often referred to as atopy, plays a crucial role in determining an individual's susceptibility to allergic diseases such as allergic rhinitis, atopic dermatitis, and asthma.

Genetic factors contribute to allergic reactions through various pathways, including the regulation of immune responses. Recent studies have highlighted the significance of epigenetic mechanisms in modulating gene expression related to allergic reactions. Epigenetics encompasses a range of biochemical modifications that influence gene activity without altering the underlying DNA sequence. These modifications include DNA methylation, histone modifications, and the action of non-coding RNAs, such as microRNAs. Such epigenetic changes can be triggered by environmental factors, including dietary components, pollutants, and microbial exposures, particularly during critical developmental windows such as prenatal and early postnatal periods [1][23][28].

Environmental exposures, especially during early life, are critical in shaping immune system development and can lead to epigenetic alterations that predispose individuals to allergies. For instance, nutritional factors, such as vitamin D and polyunsaturated fatty acids, have been shown to exert epigenetic effects that can influence immune gene expression and function [29][30]. Furthermore, the first 1000 days of life, encompassing conception through early childhood, is identified as a key period during which nutritional and environmental factors can exert significant epigenetic influences on immune system development [30].

The mechanisms by which epigenetics influences allergic responses are multifaceted. For example, epigenetic modifications can affect the differentiation and function of various immune cells, including T helper (Th) cells, which are pivotal in orchestrating allergic responses. The balance between Th1 and Th2 cell differentiation is particularly important, as a predominance of Th2 responses is associated with allergic conditions [31]. Additionally, epigenetic alterations can lead to long-lasting changes in immune cell memory, which may affect how the immune system responds to subsequent exposures to allergens [28].

Moreover, the interplay between genetic susceptibility and environmental exposures through epigenetic mechanisms is crucial in understanding the pathogenesis of allergic diseases. It has been suggested that early environmental exposures can modify gene expression related to immune tolerance, thereby influencing the risk of developing allergies later in life [32].

In summary, the mechanisms of allergic reactions are significantly influenced by genetic factors and their interaction with environmental exposures, particularly through epigenetic modifications. These modifications can alter gene expression patterns that govern immune responses, leading to the development of allergic diseases. Understanding these mechanisms is essential for developing targeted diagnostic and therapeutic strategies for managing allergies.

4 Environmental Triggers of Allergic Reactions ​

4.1 Common Allergens ​

Allergic reactions are characterized by an inappropriate immune response to otherwise harmless environmental substances, known as allergens. The underlying mechanisms of these reactions involve complex interactions between various immune cells, mediators, and environmental triggers.

At the core of allergic reactions is the role of immunoglobulin E (IgE) antibodies, which are produced by B cells in response to allergens. When an individual is sensitized to an allergen, subsequent exposure leads to the binding of the allergen to IgE that is attached to high-affinity receptors on mast cells and basophils. This cross-linking triggers the degranulation of these cells, resulting in the release of a variety of mediators such as histamine, cytokines, and other inflammatory substances, which are responsible for the immediate symptoms of allergic reactions, including itching, swelling, and bronchoconstriction [5].

The allergic response can be divided into two phases: the immediate hypersensitivity reaction and the late-phase response. The immediate phase is mediated primarily by mast cells and is characterized by the rapid release of mediators that cause acute symptoms. This is followed by a late-phase response, which is dominated by eosinophils and T lymphocytes, particularly memory T cells that secrete TH2-like cytokines such as interleukin (IL)-4, IL-5, and IL-13. These cytokines promote IgE synthesis, eosinophil development, and the perpetuation of allergic inflammation [6].

Environmental triggers of allergic reactions include a wide range of substances, such as pollen, dust mites, mold, animal dander, food proteins, and insect venoms. Each of these allergens can provoke a unique immune response depending on the individual's genetic predisposition and previous exposure [1]. For instance, in the case of food allergies, the mechanism often involves the recognition of specific protein epitopes that are altered by processing methods, leading to heightened allergenicity [33].

Moreover, the interaction between genetic factors and environmental influences plays a significant role in the development of allergic diseases. Factors such as pollution, climate change, and lifestyle alterations can exacerbate allergic responses. This interplay can influence the immune system's balance between TH1 and TH2 responses, often resulting in a skewed response favoring TH2, which is associated with allergic conditions [3].

In summary, the mechanisms of allergic reactions are multifaceted, involving an interplay of immunological responses, environmental triggers, and genetic predispositions. Understanding these mechanisms is crucial for developing targeted therapies and preventive strategies for allergic diseases.

4.2 Impact of Urbanization and Lifestyle Changes ​

Allergic reactions, classified as type I hypersensitivity reactions, occur when the immune system overreacts to normally harmless environmental antigens known as allergens. The mechanisms underlying these reactions are complex and multifaceted, involving genetic predispositions, environmental factors, and lifestyle changes that have evolved over recent decades.

The rise in allergic diseases, including asthma, allergic rhinitis, and atopic dermatitis, has been significantly associated with environmental changes linked to urbanization and modern lifestyles. Urban environments expose individuals to a range of environmental pollutants, including particulate matter, nitrogen dioxide, and ozone, which can exacerbate allergic responses. Studies have shown that urban living conditions are correlated with higher rates of allergic diseases compared to rural settings, largely due to increased exposure to these pollutants and a reduction in biodiversity, which is essential for immune system education [34][35].

Lifestyle changes have also played a critical role in the pathogenesis of allergies. The modern lifestyle characterized by increased time spent indoors, reduced contact with natural environments, and dietary modifications, such as the increased consumption of processed foods, has been linked to the development of allergic diseases. For instance, the lack of exposure to diverse microbial environments, including those found in rural settings, may hinder the proper development of the immune system, leading to an increased risk of allergic sensitization [1][36].

The interplay between environmental exposures and immune responses is critical in understanding allergic mechanisms. Environmental factors, including air pollution and allergens, influence the Th2/IgE-dominated inflammation characteristic of allergic reactions. For example, exposure to indoor and outdoor aeroallergens and air pollutants has been shown to activate inflammatory pathways that contribute to allergic sensitization and symptom exacerbation [35][37]. Furthermore, climate change has introduced additional stressors, such as extreme weather events, which can lead to increased pollen production and exposure to molds, further compounding the problem [38][39].

Moreover, the exposure to environmental toxins, including endocrine-disrupting chemicals, has been linked to alterations in cytokine production and immune system function, which may contribute to an imbalance in T-helper cell responses, particularly favoring Th2 responses associated with allergies [40]. This imbalance can enhance the production of IgE, a key mediator in allergic reactions, leading to increased sensitization and severity of allergic symptoms [24].

In summary, the mechanisms of allergic reactions are influenced by a combination of genetic predisposition and significant environmental triggers stemming from urbanization and lifestyle changes. The increased prevalence of allergies can be attributed to a complex interplay of factors, including exposure to pollutants, dietary habits, reduced microbial diversity, and altered immune responses, highlighting the need for a comprehensive understanding of these interactions to inform prevention and management strategies for allergic diseases.

5 Current and Emerging Treatments ​

5.1 Pharmacological Approaches ​

Allergic reactions are the result of inappropriate immune responses to typically harmless environmental proteins, which lead to a cascade of immunological events. The pivotal role in the pathogenesis of allergic hypersensitivity reactions is played by allergen-specific T helper (Th) cells, particularly the Th2 subset. These Th2 cells activate a complex immune reaction that triggers the release of potent mediators, enhancing the recruitment of inflammatory cells, and ultimately eliciting an inflammatory response that manifests as clinical symptoms of allergic diseases (Nauta et al., 2008) [2].

The imbalance between Th1 and Th2 responses is a key mechanism determining the development of allergies. In sensitized individuals, a dominant Th2 response is associated with the production of IgE antibodies, which bind to allergens and trigger degranulation of mast cells and basophils, releasing mediators such as histamine, leukotrienes, and cytokines. This leads to symptoms ranging from mild allergic rhinitis to severe anaphylaxis (Brotons-Canto et al., 2018) [3].

In recent years, significant advancements have been made in understanding the immunological mechanisms underlying allergic diseases. Novel immunopharmacological drugs have been developed to target various components of the allergic inflammatory response. These include therapeutic monoclonal antibodies that target cytokines, alarmins, and their receptors, as well as small-molecule modifiers of signal transduction pathways primarily mediated by Janus kinases and Bruton's tyrosine kinases. These drugs aim to intervene at distinct pathophysiological steps in the allergic response, transitioning management from merely symptomatic relief to disease-modifying therapies (Tiligada et al., 2024) [41].

Current pharmacological approaches for managing allergic diseases primarily focus on controlling symptoms and suppressing inflammation. Conventional treatments include corticosteroids and allergen immunotherapy, which, while effective, may not address the underlying causes of allergies. Some patients experience treatment-resistant inflammation or adverse reactions to these therapies, indicating a pressing need for new therapeutic strategies (Bauer et al., 2015) [42].

Recent strategies have emerged that include sublingual and oral immunotherapies aimed at inducing tolerance by administering small amounts of allergens over extended periods. However, the long duration required for significant desensitization and the potential for adverse effects have limited their widespread application (Brotons-Canto et al., 2018) [3]. Furthermore, ongoing research is focused on utilizing adjuvant immunotherapy to facilitate the reversion of the Th2 response towards a Th1 response, which could enhance the efficacy of treatment protocols (Brotons-Canto et al., 2018) [3].

The landscape of allergic disease treatment is evolving with the introduction of biologics that specifically target pathways involved in the Th2 immune response. For instance, anti-IgE antibodies and anti-type 2 cytokine monoclonal antibodies have shown promise in clinical settings, providing new avenues for treatment (van de Veen & Akdis, 2019) [43]. Additionally, understanding the role of the epithelial barrier and the microbiome in developing immune tolerance to allergens is influencing new prevention and treatment strategies (Akdis et al., 2023) [44].

In summary, the mechanisms of allergic reactions are complex and involve a sophisticated interplay of immune responses primarily driven by Th2 cells. Current and emerging pharmacological approaches aim to target these mechanisms more effectively, transitioning from symptom management to interventions that modify the disease process itself. As research continues to uncover the intricacies of allergic disease pathophysiology, new therapeutic options are anticipated to enhance patient outcomes significantly.

5.2 Immunotherapy ​

Allergic reactions are characterized by inappropriate immune responses to harmless environmental proteins, which are termed allergens. The pathogenesis of allergic diseases involves a complex interplay of immune cells and mediators, particularly the activation of allergen-specific T helper (Th) cells, predominantly Th2 cells. These Th2 cells play a pivotal role in orchestrating the immune response, leading to the release of various mediators that drive the clinical symptoms associated with allergic diseases.

The immune response to allergens typically begins with sensitization, where the immune system incorrectly identifies a harmless substance as a threat. This results in the activation of Th2 cells, which subsequently promote the production of immunoglobulin E (IgE) antibodies specific to the allergen. The binding of IgE to mast cells and basophils primes these cells for future encounters with the allergen. Upon re-exposure to the allergen, cross-linking of IgE on these effector cells triggers their degranulation, releasing potent inflammatory mediators such as histamine, leukotrienes, and cytokines. This cascade leads to the clinical manifestations of allergic reactions, which can range from mild symptoms such as sneezing and itching to severe anaphylactic reactions [2].

Recent advances in understanding the cellular and molecular mechanisms underlying allergic reactions have paved the way for the development of innovative treatments, particularly immunotherapy. Immunotherapy aims to modify the underlying immune responses rather than merely alleviating symptoms. Allergen-specific immunotherapy (AIT) has been shown to induce long-lasting tolerance to allergens, which is achieved through mechanisms such as immune deviation, where the immune response is skewed from a Th2-dominated response to a more balanced Th1 or regulatory T cell response [45].

Current immunotherapy protocols involve the administration of increasing doses of allergens, either subcutaneously or sublingually, to desensitize the immune system. This process helps to decrease the Th2 response and promote the development of IgG antibodies that can compete with IgE for allergen binding, thereby inhibiting the allergic response [46]. However, challenges remain, including the risk of adverse reactions and the lengthy duration of treatment required to achieve desensitization [3].

Emerging therapies also focus on biologics, which target specific pathways in the allergic response. For instance, monoclonal antibodies that inhibit IgE or block key cytokines involved in the Th2 response are being explored as potential treatments for allergic diseases [42]. Additionally, novel approaches such as the use of modified allergens and adjuvants aim to enhance the efficacy and safety of immunotherapy by shifting the immune response away from a Th2-dominant profile [47].

In conclusion, the mechanisms underlying allergic reactions are multifaceted, involving a dysregulated immune response primarily driven by Th2 cells and IgE. Immunotherapy represents a promising approach to modifying these underlying mechanisms, offering potential long-term relief and disease modification for individuals with allergic diseases. As research progresses, new therapeutic strategies continue to emerge, aiming to enhance the efficacy and safety of treatments for allergic conditions [41].

5.3 Future Directions in Allergy Management ​

Allergic reactions are primarily the result of inappropriate immune responses to typically harmless environmental proteins, leading to a cascade of immunological events that culminate in clinical symptoms. The underlying mechanisms involve a complex interplay between various immune cells, particularly T helper (Th) cells, and the production of immunoglobulin E (IgE). In allergic individuals, there is often an imbalance favoring a Th2 response, which is characterized by the production of cytokines such as IL-4, IL-5, and IL-13. These cytokines promote IgE production, mast cell activation, and eosinophil recruitment, all of which contribute to the inflammatory response seen in allergic diseases [2].

Recent advancements in understanding the pathophysiology of allergies have highlighted the role of the intestinal microbiota and environmental factors in shaping immune responses. The gut microbiome has been shown to influence the development of immunological tolerance to food antigens, and disruptions in this microbiota may lead to an increased risk of allergic sensitization [48]. Moreover, factors such as dietary habits, vitamin D deficiency, and early exposure to potential allergens are crucial in the development of allergies [49].

Current treatments for allergic diseases primarily focus on symptom control and inflammation suppression, often utilizing corticosteroids and antihistamines. Allergen immunotherapy (AIT) is the only causative treatment that aims to modify the immune response to allergens. However, traditional AIT methods require long-term commitment and may not be suitable for all patients, particularly those with food allergies [50].

Emerging therapeutic strategies are centered on the development of biologics and novel immunotherapies. These include monoclonal antibodies targeting IgE and type 2 cytokines, as well as small-molecule inhibitors aimed at key signaling pathways involved in the allergic response [42]. The potential for personalized medicine approaches is also gaining traction, where treatments are tailored based on specific biomarkers and individual patient profiles [43].

Looking towards the future, research is increasingly focused on innovative methods of allergen immunotherapy, including oral and intralymphatic routes of administration, as well as the development of hypoallergenic products and more effective adjuvants [50]. Additionally, there is a push to better understand the role of environmental factors, such as climate change and pollutants, in allergy prevalence, which may lead to more effective prevention strategies [44].

In summary, the mechanisms of allergic reactions involve a complex immune response primarily mediated by Th2 cells and IgE, with significant contributions from environmental factors and microbiota. Current treatments are evolving, with an emphasis on biologics and personalized approaches, while future directions are focused on improving immunotherapy methods and understanding the broader environmental influences on allergy development.

6 Conclusion ​

The mechanisms of allergic reactions are complex and multifaceted, involving the interplay of genetic predisposition, environmental factors, and immune responses. Key findings highlight the critical role of immunoglobulin E (IgE) in mediating immediate hypersensitivity reactions through its interactions with mast cells and basophils. The activation of these effector cells results in the release of pro-inflammatory mediators that lead to the clinical manifestations of allergic diseases. Furthermore, cytokines produced by T helper type 2 (Th2) cells play a pivotal role in both the sensitization and elicitation phases of allergic reactions, contributing to chronic inflammation. Genetic predispositions, particularly atopy, and epigenetic modifications significantly influence individual susceptibility to allergies, further complicating the pathophysiology of these conditions. Environmental triggers, including common allergens and urbanization, exacerbate allergic responses and highlight the urgent need for effective preventive and therapeutic strategies. Current treatments primarily focus on symptom management, but emerging therapies such as biologics and immunotherapy offer promising avenues for modifying the underlying disease processes. Future research should aim to explore personalized treatment approaches and the impact of environmental factors on allergy development, ultimately leading to improved management strategies for allergic diseases.

References ​

  • [1] Robbi Miguel G Falcon;Salvador Eugenio C Caoili. Immunologic, genetic, and ecological interplay of factors involved in allergic diseases.. Frontiers in allergy(IF=3.1). 2023. PMID:37601647. DOI: 10.3389/falgy.2023.1215616.
  • [2] Alma J Nauta;Ferdi Engels;Leon M Knippels;Johan Garssen;Frans P Nijkamp;Frank A Redegeld. Mechanisms of allergy and asthma.. European journal of pharmacology(IF=4.7). 2008. PMID:18410921. DOI: 10.1016/j.ejphar.2008.02.094.
  • [3] Ana Brotons-Canto;Nekane Martín-Arbella;Carlos Gamazo;Juan M Irache. New pharmaceutical approaches for the treatment of food allergies.. Expert opinion on drug delivery(IF=5.4). 2018. PMID:27732129. DOI: 10.1080/17425247.2016.1247805.
  • [4] Stefanie Gilles;Cezmi Akdis;Roger Lauener;Peter Schmid-Grendelmeier;Thomas Bieber;Georg Schäppi;Claudia Traidl-Hoffmann. The role of environmental factors in allergy: A critical reappraisal.. Experimental dermatology(IF=3.1). 2018. PMID:30099779. DOI: 10.1111/exd.13769.
  • [5] D Y Leung. Molecular basis of allergic diseases.. Molecular genetics and metabolism(IF=3.5). 1998. PMID:9608537. DOI: 10.1006/mgme.1998.2682.
  • [6] O Jirapongsananuruk;D Y Leung. Clinical applications of cytokines: new directions in the therapy of atopic diseases.. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology(IF=4.7). 1997. PMID:9236494. DOI: 10.1016/S1081-1206(10)63078-5.
  • [7] Marco Averbeck;Carl Gebhardt;Frank Emmrich;Regina Treudler;Jan C Simon. Immunologic principles of allergic disease.. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG(IF=3.8). 2007. PMID:17976144. DOI: 10.1111/j.1610-0387.2007.06538.x.
  • [8] Melanie L Conrad;Gabriela Barrientos;Xuejun Cai;Saikat Mukherjee;Mrinmoy Das;Emmanuel Stephen-Victor;Hani Harb. Regulatory T cells and their role in allergic disease.. Allergy(IF=12.0). 2025. PMID:40497455. DOI: 10.1111/all.16326.
  • [9] Jill A Poole;Lanny J Rosenwasser. The role of immunoglobulin E and immune inflammation: implications in allergic rhinitis.. Current allergy and asthma reports(IF=4.6). 2005. PMID:15842964. DOI: 10.1007/s11882-005-0045-5.
  • [10] Alexander Eggel;Theodore S Jardetzky. Structural and Functional Insights Into IgE Receptor Interactions and Disruptive Inhibition.. Immunological reviews(IF=8.3). 2025. PMID:40305523. DOI: 10.1111/imr.70031.
  • [11] Dana Greene;Jamie Moore Fried;Julie Wang. IgE in Allergic Diseases.. Immunological reviews(IF=8.3). 2025. PMID:40862531. DOI: 10.1111/imr.70057.
  • [12] Xiao-Jing Ling;Ji-Fu Wei;Ying Zhu. Aiming to IgE: Drug development in allergic diseases.. International immunopharmacology(IF=4.7). 2023. PMID:37348229. DOI: 10.1016/j.intimp.2023.110495.
  • [13] Ming Zhang;Richard F Murphy;Devendra K Agrawal. Decoding IgE Fc receptors.. Immunologic research(IF=3.1). 2007. PMID:17496343. DOI: 10.1007/BF02686092.
  • [14] J F Gauchat;S Henchoz;G Mazzei;J P Aubry;T Brunner;H Blasey;P Life;D Talabot;L Flores-Romo;J Thompson. Induction of human IgE synthesis in B cells by mast cells and basophils.. Nature(IF=48.5). 1993. PMID:7690905. DOI: 10.1038/365340a0.
  • [15] Lars Hellman. Regulation of IgE homeostasis, and the identification of potential targets for therapeutic intervention.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie(IF=7.5). 2007. PMID:17145160. DOI: 10.1016/j.biopha.2006.10.001.
  • [16] Pascal Gasser;Alexander Eggel. Targeting IgE in allergic disease.. Current opinion in immunology(IF=5.8). 2018. PMID:29986302. DOI: 10.1016/j.coi.2018.05.015.
  • [17] Adrian M Piliponsky;Gerald J Gleich;Arnon Nagler;Ilan Bar;Francesca Levi-Schaffer. Non-IgE-dependent activation of human lung- and cord blood-derived mast cells is induced by eosinophil major basic protein and modulated by the membrane form of stem cell factor.. Blood(IF=23.1). 2003. PMID:12393403. DOI: 10.1182/blood-2002-05-1488.
  • [18] Petr Draber;Ivana Halova;Iva Polakovicova;Toshiaki Kawakami. Signal transduction and chemotaxis in mast cells.. European journal of pharmacology(IF=4.7). 2016. PMID:25941081. DOI: .
  • [19] B S Bochner;R P Schleimer. Mast cells, basophils, and eosinophils: distinct but overlapping pathways for recruitment.. Immunological reviews(IF=8.3). 2001. PMID:11292027. DOI: 10.1034/j.1600-065x.2001.790101.x.
  • [20] P Korošec;B F Gibbs;M Rijavec;A Custovic;P J Turner. Important and specific role for basophils in acute allergic reactions.. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology(IF=5.2). 2018. PMID:29431885. DOI: 10.1111/cea.13117.
  • [21] S P Peters;R M Naclerio;R P Schleimer;D W MacGlashan;U Pipkorn;L M Lichtenstein. The pharmacologic control of mediator release from human basophils and mast cells.. Respiration; international review of thoracic diseases(IF=3.8). 1986. PMID:3494282. DOI: 10.1159/000195109.
  • [22] Donata Vercelli. Genetic polymorphism in allergy and asthma.. Current opinion in immunology(IF=5.8). 2003. PMID:14630192. DOI: 10.1016/j.coi.2003.09.005.
  • [23] José A Cañas;Rafael Núñez;Anyith Cruz-Amaya;Francisca Gómez;María J Torres;Francisca Palomares;Cristobalina Mayorga. Epigenetics in Food Allergy and Immunomodulation.. Nutrients(IF=5.0). 2021. PMID:34959895. DOI: 10.3390/nu13124345.
  • [24] Hani Harb;Harald Renz. Update on epigenetics in allergic disease.. The Journal of allergy and clinical immunology(IF=11.2). 2015. PMID:25567039. DOI: .
  • [25] Mayumi Tamari; ShotaTanaka;Tomomitsu Hirota. Genome-Wide Association Studies of Allergic Diseases.. Allergology international : official journal of the Japanese Society of Allergology(IF=6.7). 2013. PMID:28942987. DOI: 10.2332/allergolint.13-RAI-0539.
  • [26] Mayumi Tamari;Shota Tanaka;Tomomitsu Hirota. Genome-wide association studies of allergic diseases.. Allergology international : official journal of the Japanese Society of Allergology(IF=6.7). 2013. PMID:23439055. DOI: 10.2332/allergolint.13-RAI-0539.
  • [27] Leigh Matthew Marsh;Petra Ina Pfefferle;Olaf Pinkenburg;Harald Renz. Maternal signals for progeny prevention against allergy and asthma.. Cellular and molecular life sciences : CMLS(IF=6.2). 2011. PMID:21369709. DOI: 10.1007/s00018-011-0644-3.
  • [28] Jonathan G Moggs;Rémi Terranova;Michael E Kammüller;Salah-Dine Chibout;Victoria Chapman;Rebecca J Dearman;Ian Kimber. Regulation of allergic responses to chemicals and drugs: possible roles of epigenetic mechanisms.. Toxicological sciences : an official journal of the Society of Toxicology(IF=4.1). 2012. PMID:22705809. DOI: 10.1093/toxsci/kfs207.
  • [29] Nathalie Acevedo;Bilal Alashkar Alhamwe;Luis Caraballo;Mei Ding;Antonio Ferrante;Holger Garn;Johan Garssen;Charles S Hii;James Irvine;Kevin Llinás-Caballero;Juan Felipe López;Sarah Miethe;Khalida Perveen;Elke Pogge von Strandmann;Milena Sokolowska;Daniel P Potaczek;Betty C A M van Esch. Perinatal and Early-Life Nutrition, Epigenetics, and Allergy.. Nutrients(IF=5.0). 2021. PMID:33668787. DOI: 10.3390/nu13030724.
  • [30] Margherita Di Costanzo;Nicoletta De Paulis;Maria Elena Capra;Giacomo Biasucci. Nutrition during Pregnancy and Lactation: Epigenetic Effects on Infants' Immune System in Food Allergy.. Nutrients(IF=5.0). 2022. PMID:35565735. DOI: 10.3390/nu14091766.
  • [31] D J Martino;Susan L Prescott. Silent mysteries: epigenetic paradigms could hold the key to conquering the epidemic of allergy and immune disease.. Allergy(IF=12.0). 2010. PMID:19796189. DOI: 10.1111/j.1398-9995.2009.02186.x.
  • [32] Christine Quake;Kari C Nadeau. The role of epigenetic mediation and the future of food allergy research.. Seminars in cell & developmental biology(IF=6.0). 2015. PMID:26150170. DOI: 10.1016/j.semcdb.2015.07.002.
  • [33] Sebastian A Jensen;Alessandro Fiocchi;Ton Baars;Galateja Jordakieva;Anna Nowak-Wegrzyn;Isabella Pali-Schöll;Stefano Passanisi;Christina L Pranger;Franziska Roth-Walter;Kristiina Takkinen;Amal H Assa'ad;Carina Venter;Erika Jensen-Jarolim; . Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines update - III - Cow's milk allergens and mechanisms triggering immune activation.. The World Allergy Organization journal(IF=4.3). 2022. PMID:36185551. DOI: 10.1016/j.waojou.2022.100668.
  • [34] Liza Bronner Murrison;Eric B Brandt;Jocelyn Biagini Myers;Gurjit K Khurana Hershey. Environmental exposures and mechanisms in allergy and asthma development.. The Journal of clinical investigation(IF=13.6). 2019. PMID:30741719. DOI: .
  • [35] Lorenzo Cecchi;Gennaro D'Amato;Isabella Annesi-Maesano. External exposome and allergic respiratory and skin diseases.. The Journal of allergy and clinical immunology(IF=11.2). 2018. PMID:29519451. DOI: 10.1016/j.jaci.2018.01.016.
  • [36] Shifaa Suhayl Alkotob;Cade Cannedy;Katharina Harter;Hesam Movassagh;Bibek Paudel;Mary Prunicki;Vanitha Sampath;Tamara Schikowski;Eric Smith;Qi Zhao;Claudia Traidl-Hoffmann;Kari C Nadeau. Advances and novel developments in environmental influences on the development of atopic diseases.. Allergy(IF=12.0). 2020. PMID:33037680. DOI: 10.1111/all.14624.
  • [37] Nathalie Acevedo;Josefina Zakzuk;Luis Caraballo. House Dust Mite Allergy Under Changing Environments.. Allergy, asthma & immunology research(IF=4.3). 2019. PMID:31172715. DOI: 10.4168/aair.2019.11.4.450.
  • [38] Vanitha Sampath;Juan Aguilera;Mary Prunicki;Kari C Nadeau. Mechanisms of climate change and related air pollution on the immune system leading to allergic disease and asthma.. Seminars in immunology(IF=7.8). 2023. PMID:37105834. DOI: 10.1016/j.smim.2023.101765.
  • [39] M D Amato;L Cecchi;I Annesi-Maesano;G D Amato. News on Climate Change, Air Pollution, and Allergic Triggers of Asthma.. Journal of investigational allergology & clinical immunology(IF=4.8). 2018. PMID:29345235. DOI: 10.18176/jiaci.0228.
  • [40] San-Nan Yang;Chong-Chao Hsieh;Hsuan-Fu Kuo;Min-Sheng Lee;Ming-Yii Huang;Chang-Hung Kuo;Chih-Hsing Hung. The effects of environmental toxins on allergic inflammation.. Allergy, asthma & immunology research(IF=4.3). 2014. PMID:25374746. DOI: 10.4168/aair.2014.6.6.478.
  • [41] Ekaterini Tiligada;Daria Gafarov;Maria Zaimi;Joana Vitte;Francesca Levi-Schaffer. Novel Immunopharmacological Drugs for the Treatment of Allergic Diseases.. Annual review of pharmacology and toxicology(IF=13.1). 2024. PMID:37722722. DOI: 10.1146/annurev-pharmtox-051623-091038.
  • [42] Rebecca N Bauer;Monali Manohar;Anne Marie Singh;David C Jay;Kari C Nadeau. The future of biologics: applications for food allergy.. The Journal of allergy and clinical immunology(IF=11.2). 2015. PMID:25662303. DOI: .
  • [43] Willem van de Veen;Mübeccel Akdis. The use of biologics for immune modulation in allergic disease.. The Journal of clinical investigation(IF=13.6). 2019. PMID:30882368. DOI: .
  • [44] Cezmi A Akdis;Mübeccel Akdis;Scott D Boyd;Vanitha Sampath;Stephen J Galli;Kari C Nadeau. Allergy: Mechanistic insights into new methods of prevention and therapy.. Science translational medicine(IF=14.6). 2023. PMID:36652536. DOI: 10.1126/scitranslmed.add2563.
  • [45] D Campbell;R H DeKruyff;D T Umetsu. Allergen immunotherapy: novel approaches in the management of allergic diseases and asthma.. Clinical immunology (Orlando, Fla.)(IF=3.8). 2000. PMID:11112358. DOI: 10.1006/clim.2000.4926.
  • [46] Ioana Agache;Magdalena Zemelka-Wiącek;Mohamed H Shamji;Marek Jutel. Immunotherapy: State-of-the-art review of therapies and theratypes.. The Journal of allergy and clinical immunology(IF=11.2). 2022. PMID:36328808. DOI: 10.1016/j.jaci.2022.10.007.
  • [47] Laurian Jongejan;Ronald van Ree. Modified allergens and their potential to treat allergic disease.. Current allergy and asthma reports(IF=4.6). 2014. PMID:25269402. DOI: 10.1007/s11882-014-0478-9.
  • [48] Massimo De Martinis;Maria Maddalena Sirufo;Mariano Suppa;Lia Ginaldi. New Perspectives in Food Allergy.. International journal of molecular sciences(IF=4.9). 2020. PMID:32098244. DOI: 10.3390/ijms21041474.
  • [49] Scott H Sicherer;Donald Y M Leung. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2011.. The Journal of allergy and clinical immunology(IF=11.2). 2012. PMID:22196526. DOI: 10.1016/j.jaci.2011.11.016.
  • [50] Lara Šošić;Marta Paolucci;Stephan Flory;Fadi Jebbawi;Thomas M Kündig;Pål Johansen. Allergen immunotherapy: progress and future outlook.. Expert review of clinical immunology(IF=3.7). 2023. PMID:37122076. DOI: 10.1080/1744666X.2023.2209319.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Allergic Reactions · Immunoglobulin E · Mast Cells · Cytokines · Environmental Triggers

© 2025 MaltSci